Erslev A J
Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107.
Semin Oncol. 1992 Jun;19(3 Suppl 8):14-8.
Recombinant human erythropoietin (r-HuEPO) has been shown to be remarkably effective in raising the hemoglobin concentrations and improving the quality of life of patients with chronic renal disease. It is currently under investigation for treatment of patients with nonrenal anemias associated with cancer chemotherapy, acquired immunodeficiency syndrome, rheumatoid arthritis, and other chronic illnesses. To date, investigators have shown that patients with mild anemia and low endogenous erythropoietin (EPO) production may be good candidates for such treatment. Conversely, studies have shown that patients with severe anemia and serum EPO concentrations of above 500 mU/mL apparently do not respond to doses used for patients with mild anemia or chronic renal disease. Large doses of r-HuEPO may be of use in such patients, and clinical trials are in progress to determine if it is at least possible to make these patients transfusion-independent.
重组人促红细胞生成素（r-HuEPO）已被证明在提高慢性肾病患者的血红蛋白浓度和改善其生活质量方面非常有效。目前正在对其用于治疗与癌症化疗、获得性免疫缺陷综合征、类风湿性关节炎及其他慢性疾病相关的非肾性贫血患者进行研究。迄今为止，研究人员已表明，轻度贫血且内源性促红细胞生成素（EPO）产生量低的患者可能是此类治疗的合适人选。相反，研究表明，重度贫血且血清EPO浓度高于500 mU/mL的患者显然对用于轻度贫血患者或慢性肾病患者的剂量无反应。大剂量的r-HuEPO可能对此类患者有用，目前正在进行临床试验以确定是否至少有可能使这些患者不再依赖输血。
